No. |
DrugBank |
薬物名(臨床試験情報から抽出) |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 | ALTU-135 | 1件: Altu-135; | - |
- |
- |
1件: 299 |
2 | AZD-1236 | 1件: Azd1236; | - |
- |
- |
1件: 299 |
3 | Acebilustat | 1件: Acebilustat; | - |
- |
- |
1件: 299 |
4 | Acetate | 76件: 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate; | - |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
5 | Acetylcysteine | 8件: Acetylcysteine; Acetylcysteine sodium; Glatiramer acetate, n-acetylcysteine; N acetylcysteine; N-acetylcysteine; N-acetylcysteine (nac); N-acetylcysteine capsule; N-acetylcysteine, (nac); | D00221 |
- |
- |
16件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 96, 97, 111, 164, 233, 298, 299 |
6 | Ajulemic acid | 2件: Ajulemic acid; Resunab, ajulemic acid, anabasum; | D11312 |
1件: CNR2 |
1件: Neuroactive ligand-receptor interaction |
3件: 50, 51, 299 |
7 | Alendronic acid | 1件: Alendronic acid; | D00939 D07119 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
7件: 19, 41, 46, 50, 271, 274, 299 |
8 | Alginic acid | 1件: Alginic acid; | D02324 |
- |
- |
3件: 51, 53, 299 |
9 | Alpha-1-proteinase inhibitor | - | - |
- |
- |
3件: 231, 298, 299 |
10 | Amikacin | 10件: Amikacin; Amikacin nebulization; Iv amikacin; Liposomal amikacin (arikace™); Liposomal amikacin for inhalation; Liposomal amikacin for inhalation (arikayce™) using the pari investigational eflow® nebulizer.; Nebulization of amikacin during niv (rr: 15 cycles/minute); Nebulization of amikacin during niv (rr: 25 cycles/minute); Slit amikacin; Slit(tm) amikacin; | D00865 D02543 |
- |
- |
2件: 60, 299 |
11 | Amiloride | 6件: Amiloride; Amiloride hcl; Amiloride hydrochloride; Amiloride hydrochloride, 2 h2o; Amiloride solution for inhalation; Hydrochlorothiazide/amiloride; | D00649 D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
3件: 13, 225, 299 |
12 | Amitriptyline | 3件: Amitriptyline; Amitriptyline, fluoxetine and tramadol alone (control group); Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); | D00809 D07448 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 78, 226, 299 |
13 | Amphotericin B | 2件: Amphotericin b; Liposomal amphotericin b (ambisome®); | D00203 |
- |
- |
1件: 299 |
14 | Anakinra | 8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra / kineret; Anakinra and peg stnf-r1; Kineret® (anakinra); Kineret® or anakinra; Response to anakinra associated with methotrexate; | D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
15 | Aspartic acid | - | D00013 |
- |
- |
3件: 13, 75, 299 |
16 | Ataluren | 9件: Ataluren; Ataluren (ptc124); Ataluren (ptc124®); Ataluren 1000 mg; Ataluren 1000mg; Ataluren 125 mg; Ataluren 125mg; Ataluren 250 mg; Ataluren 250mg; | D09323 |
- |
- |
6件: 19, 113, 140, 246, 299, 329 |
17 | Atorvastatin | 9件: Atorvastatin; Atorvastatin 10mg; Atorvastatin 20mg; Atorvastatin calcium; Atorvastatin tablet 20 mg; Interferon beta treatment to add-on atorvastatin treatment; Interferon beta-1b/atorvastatin group; Lisinopril, losartan, and atorvastatin; Untreated to atorvastatin treatment; | D00258 D00887 D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
18 | Avibactam | 2件: Avibactam; Ceftazidime/avibactam; | - |
- |
- |
1件: 299 |
19 | Azithromycin | 10件: Azithromycin; Azithromycin (zitromax°); Azithromycin + metronidazole; Azithromycin + n-acetylcystein + inhaled corticosteroid; Azithromycin 250 mg tablets; Azithromycin 250mg capsule; Azithromycin 500 mg film-coated tablet; Azithromycin dihydrate; Po azithromycin; Study medication, azithromycin; | D02134 D06390 D07486 |
- |
- |
6件: 13, 84, 85, 96, 228, 299 |
20 | Aztreonam | 8件: Aztreonam; Aztreonam for inhalation (ai); Aztreonam for inhalation solution (azli); Aztreonam lysine; Aztreonam lysine for inhalation; Aztreonam lysine for inhalation (azli); Nasal aztreonam; Oral aztreonam; | D00240 D06558 |
- |
- |
2件: 228, 299 |
21 | Bacitracin | - | D00128 D03047 D03048 |
- |
- |
1件: 299 |
22 | Broccoli | 3件: Broccoli; Broccoli sprouts; Jojoba oil with broccoli sprout extract; | - |
- |
- |
2件: 36, 299 |
23 | Budesonide | 39件: 0.5 mg budesonide effervescent tablet for orodispersible use; 1 mg budesonide effervescent tablet for orodispersible use; 1mg budesonide effervescent tablet for orodispersible use; 2mg budesonide effervescent tablet for orodispersible use; Budesonide; Budesonide ( zentacort capsules 3mg ); Budesonide (6 mg); Budesonide (9 mg); Budesonide 0.5mg orodispersible tablet twice daily; Budesonide 1mg orodispersible tablet twice daily; Budesonide 6 mg capsules, hard (bux-pvii prototype); Budesonide 9 mg capsules, hard (bux-pv); Budesonide 9 mg capsules, hard (bux-pvii prototype); Budesonide [0.4mg/ml] viscous suspension; Budesonide mmx 6 mg tablet; Budesonide mmx®; Budesonide mmx® 6 mg; Budesonide mmx® 9 mg; Budesonide oral suspension; Budesonide oral suspension [0.2 mg/ml]; Budesonide plus prevacid; Budesonide-formoterol single inhaler; Budesonide-mmx; Budesonide-mmx®; Budesonide-mmx® 6 mg; Budesonide-mmx® 9 mg; Budesonide-mmx™; Budesonide/formoterol; Combination oral budesonide and rectal hydrocortisone; Formoterol/budesonide; High dose of budesonide; Inhaled/swallowed budesonide; Methylprednisolone or budesonide; Oral budesonide; Oral budesonide suspension (mb-9); Oral budesonide suspension (obs); Oral viscous budesonide; Oral viscous budesonide (ovb); Viscous/swallowed budesonide; | D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
10件: 66, 85, 93, 94, 95, 96, 97, 98, 228, 299 |
24 | Burlulipase | 1件: Burlulipase; | - |
- |
- |
1件: 299 |
25 | CR002 | 2件: Cr002; Cr002 liquid api; | - |
- |
- |
1件: 299 |
26 | Calcifediol | 1件: Calcifediol; | D00122 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
2件: 113, 299 |
27 | Calcium | 25件: Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Rosuvastatin calcium; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium; | - |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
28 | Calcium Carbonate | 3件: Amorphous calcium carbonate; Calcium carbonate; Calcium carbonate and alphacalcidol; | D00932 D10802 |
- |
- |
7件: 13, 19, 46, 75, 96, 235, 299 |
29 | Calfactant | 1件: Calfactant; | D03317 |
- |
- |
1件: 299 |
30 | Carbonate ion | - | - |
- |
- |
10件: 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
31 | Cavosonstat | 1件: Cavosonstat; | D10916 |
- |
- |
1件: 299 |
32 | Cefepime | 4件: Cefepime; Cefepime dihydrochloride monohydrate; Continuous infusion cefepime; Intermittent, short infusion cefepime; | D02376 |
- |
- |
2件: 60, 299 |
33 | Ceftaroline fosamil | - | D08884 |
- |
- |
1件: 299 |
34 | Ceftazidime | 7件: Ceftazidime; Ceftazidime and tobramycin; Ceftazidime pentahydrate; Ceftazidime/avibactam; Continuous infusion ceftazidime; Intermittent, short infusion ceftazidime; Iv ceftazidime; | D00921 D07654 |
- |
- |
1件: 299 |
35 | Ceftolozane | 2件: Ceftolozane; Ceftolozane/tazobactam; | D10097 |
- |
- |
1件: 299 |
36 | Chlorhexidine | 5件: 2% chlorhexidine solution wipes; 4% chlorhexidine gluconate liquid skin cleanser; Chlorhexidine; Chlorhexidine gluconate; Chlorhexidine gluconate oral rinse; | D00858 D01345 D03463 D07668 |
- |
- |
2件: 86, 299 |
37 | Chloride ion | - | - |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
38 | Cholecalciferol | 9件: 5000 iu of cholecalciferol; Calcium and cholecalciferol; Cholecalciferol; Cholecalciferol (vitamin d3); Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol and c. xanthorrhiza; Cholecalciferol concentrate; Cholecalciferol, vitamin d3; | D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
15件: 6, 13, 19, 20, 34, 46, 49, 53, 60, 65, 96, 97, 228, 298, 299 |
39 | Choline | 6件: Bis-choline tetrathiomolybdate; Choline; Choline chloride; Choline supplementation; Diazoxide choline controlled-release tablet; Vitamin: choline bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1; | D07690 |
- |
- |
4件: 65, 171, 193, 299 |
40 | Ciprofloxacin | 14件: Cipro (ciprofloxacin, bayq3939); Ciprofloxacin; Ciprofloxacin (cipro inhale, bayq3939); Ciprofloxacin (cipro, bayq3939); Ciprofloxacin (ciproxin); Ciprofloxacin dispersion for inhalation; Ciprofloxacin dpi; Ciprofloxacin for inhalation; Ciprofloxacin hydrochloride; Ciprofloxacin hydrochloride monohydrate; Fixed dose combination ciprofloxacin/celecoxib; Oral ciprofloxacin; Oral ciprofloxacin plus inhaled colistin; Po ciprofloxacin; | D00186 D02216 |
- |
- |
5件: 2, 60, 96, 97, 299 |
41 | Clarithromycin | 6件: Biaxin ( clarithromycin); Clarithromycin; Lansoprazole, amoxicillin, clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Rifabutin, clarithromycin, and clofazimine; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication); | D00276 |
- |
- |
8件: 6, 63, 84, 96, 97, 222, 228, 299 |
42 | Clavulanic acid | - | D07711 |
- |
- |
1件: 299 |
43 | Cobamamide | 1件: Cobamamide; | D00042 |
- |
- |
1件: 299 |
44 | Colistimethate | 6件: Colistimethate; Colistimethate 75 mg inhaled two times daily; Colistimethate sodium; Colistimethate sodium (a component); Colistimethate sodium (ban, usan), colistimethatum natricum, colistin sodium methanesulfonate; Colistimethate sodium (promixin); | D02049 |
- |
- |
1件: 299 |
45 | Colistin | 6件: Colistimethate sodium (ban, usan), colistimethatum natricum, colistin sodium methanesulfonate; Colistin; Colistin cf; Colistin forest - trockenstechampullen mit lösungsmittel; Colistin mesilate sodium; Oral ciprofloxacin plus inhaled colistin; | D02138 D07746 |
- |
- |
1件: 299 |
46 | Curcumin | 5件: Bio-enhanced curcumin soft gelatin capsule; Curcumin; Curcumin (longvida™); Curcumin supplement; Ifn beta 1 a + curcumin (bcm 95); | - |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
47 | Cyanocobalamin | - | D00166 D03615 D03616 D03617 |
- |
- |
12件: 6, 13, 49, 62, 86, 96, 97, 201, 229, 254, 284, 299 |
48 | Cysteamine | 9件: Cystagon (cysteamine bitartrate) immediate-release capsules; Cystagon® (cysteamine bitartrate); Cysteamine; Cysteamine (mercaptamine) viscous solution; Cysteamine bitartrate; Cysteamine bitartrate (cystagon); Cysteamine bitartrate (inn: mercaptamine bitartrate ); Cysteamine bitartrate delayed-release capsules (rp103); Cysteamine hydrochloride; | D03634 D03635 |
- |
- |
4件: 8, 19, 21, 299 |
49 | D-glucose | 3件: 2-deoxy-2 [f-18] fluoro-2-d-glucose; [18f]fluoro-2-deoxy-2-d-glucose; D-glucose; | D00009 |
- |
- |
6件: 6, 13, 49, 86, 88, 299 |
50 | DL-dimyristoylphosphatidylcholine | - | - |
- |
- |
1件: 299 |
51 | DL-dimyristoylphosphatidylglycerol | - | - |
- |
- |
1件: 299 |
52 | Denosumab | 4件: Denosumab; Denosumab - immunoglobulin g2 human monoclonal antibody to rank ligand; Pralia 60 mg subcutaneous injection syringe(denosumab); Pralia 60mg subcutaneous injection syringe(denosumab); | D03684 |
1件: TNFSF11 |
7件: Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis |
7件: 46, 50, 93, 95, 96, 274, 299 |
53 | Denufosol | 4件: Denufosol; Denufosol tetrasodium (ins37217); Denufosol tetrasodium (ins37217) inhalation solution; Denufosol tetrasodium inhalation solution; | D03685 |
- |
- |
1件: 299 |
54 | Desoxyribonuclease | 2件: Desoxyribonuclease; Recombiant human desoxyribonuclease ( rhdnase); | - |
- |
- |
1件: 299 |
55 | Dexamethasone | 35件: Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Bupivacaine/epinephrine/dexamethasone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Control intervention (no dexamethasone); Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Dexamethasone; Dexamethasone (1 cycle); Dexamethasone (4 cycles); Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0,5mg; Dexamethasone 0.5mg tablet; Dexamethasone 21-phosphate; Dexamethasone 2mg tablets; Dexamethasone abcur; Dexamethasone and rituximab; Dexamethasone parotid irrigation; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dexamethasone sodium phosphate 250 mg/10 ml solution; Dexamethasone sodium phosphate ph. eur.; Dexamethasone soduim phosphate; Dexamethasone, 40 mg; High dose dexamethasone pulses; Intraarticular dexamethasone; Intravenous dexamethasone 1 mg; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Lenalidomide, dexamethasone and cyclophosphamide; Melphalan, thalidomide and dexamethasone; Mmf and dexamethasone; Peri-neural dexamethasone 1 mg; Pomalidomide and dexamethasone; | D00292 D00975 D01510 D01615 D01632 D01948 D02174 D02591 D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
56 | Digitoxin | 1件: Digitoxin; | D00297 |
4件: ATP1A1, ATP1A2, ATP1A3, ATP1A4 |
18件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 299 |
57 | Doconexent | - | - |
- |
- |
7件: 6, 49, 90, 94, 240, 299, 301 |
58 | Doripenem | 2件: Doripenem; Doripenem hydrate; | D03895 |
- |
- |
1件: 299 |
59 | Dornase alfa | 4件: Dornase alfa; Dornase alfa (pulmozyme); Dornase alfa [pulmozyme®]; Pulmozyme (dornase alfa); | D03896 |
- |
- |
2件: 53, 299 |
60 | Doxycycline | 7件: Antimicrobial therapy: co-trimoxazole or doxycycline; Doxycycline; Doxycycline 100 mg capsules; Doxycycline hyclate; Doxycycline hyclate ph.eur; Interferon beta 1a, oral doxycycline; Treatment with systemic therapy (doxycycline); | D00307 D02129 D03903 D03904 D07876 |
- |
- |
15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
61 | ELX-02 | 1件: Elx-02; | - |
- |
- |
2件: 19, 299 |
62 | Ebselen | 4件: Ebselen; Spi-1005 ebselen 200mg capsule x1; Spi-1005 ebselen 200mg capsule x2; Spi-1005 ebselen 200mg capsule x3; | - |
- |
- |
1件: 299 |
63 | Elexacaftor | 2件: Elexacaftor; Elexacaftor-tezacaftor-ivacaftor exposure; | D11507 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
64 | Epigallocatechin gallate | 2件: Coconut oil and epigallocatechin gallate; Epigallocatechin gallate; | - |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
65 | Ergocalciferol | 2件: Ergocalciferol; Ergocalciferol (vitamin d2); | D00187 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
5件: 46, 84, 96, 97, 299 |
66 | Esomeprazole | 3件: Esomeprazole; Esomeprazole 20 mg; Nexium (esomeprazole magnesium); | D01984 D04056 D07917 D09339 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 6, 46, 86, 98, 298, 299 |
67 | Estradiol | 8件: 5% lidocaine/5 mg/ml estradiol compound cream; Estradiol; Estradiol 2 mg; Estradiol hemihydrate; Ethinyl estradiol; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Ortho-cyclen, ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg; | D00105 D01413 D01617 D01953 D04061 D04063 D04064 D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
5件: 13, 46, 49, 226, 299 |
68 | Ethambutol | 1件: Ethambutol; | D00878 D07925 |
- |
- |
2件: 84, 299 |
69 | Ethanol | 7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; | D00068 D02798 D04855 D06542 |
- |
- |
49件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 58, 61, 63, 64, 65, 66, 81, 84, 85, 86, 88, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 279, 280, 283, 284, 285, 288, 298, 299, 300, 331 |
70 | Ethinylestradiol | 1件: Ethinylestradiol; | D00554 |
1件: ESR1 |
8件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
4件: 13, 46, 49, 299 |
71 | Fenretinide | 1件: Fenretinide; | D04162 |
2件: RARA, RARB |
8件: Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
1件: 299 |
72 | Ferric carboxymaltose | 2件: Ferric carboxymaltose; Intravenous administration of ferric carboxymaltose; | D08920 |
- |
- |
4件: 86, 96, 97, 299 |
73 | Fish oil | 10件: Combination fish oil and borage seed oil; Combination of fish oil and colesevelam; Fish oil; Fish oil concentrate; Fish oil supplement; Fish oil, gamma-linolenic acid; Fish oil, rich in omega-3-acids; Fish oil,rich in omega 3 acids; Lipoic acid (la) with fish oil and la without fish oil; Omega-3 fatty acid fish oil supplement; | - |
- |
- |
7件: 13, 46, 49, 66, 96, 260, 299 |
74 | Flucloxacillin | 3件: Flucloxacillin; Flucloxacillin 250mg/5ml sugar-free powder for oral solution; Flucloxacillin sodium; | D01249 D04196 D07965 |
- |
- |
1件: 299 |
75 | Fluticasone | 5件: Flovent (fluticasone propionate); Fluticasone; Fluticasone mdi; Fluticasone propionate; Swallowed fluticasone; | D07981 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
4件: 98, 228, 299, 306 |
76 | Fluticasone propionate | 2件: Flovent (fluticasone propionate); Fluticasone propionate; | D01708 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
4件: 98, 228, 299, 306 |
77 | Formoterol | 4件: Budesonide-formoterol single inhaler; Budesonide/formoterol; Formoterol; Formoterol/budesonide; | D01373 D05277 D07990 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 85, 228, 299, 306 |
78 | Gallium nitrate | 1件: Gallium nitrate; | D00940 |
- |
- |
1件: 299 |
79 | Garlic | 2件: Boots high strength garlic odour controlled; Garlic; | - |
- |
- |
1件: 299 |
80 | Genistein | 4件: Genistein; Genistein (unconjugated isoflavones 100); Genistein aglycone; Unconjugated isoflavones 100 (pti g-4660, 87% genistein); | D11680 |
- |
- |
2件: 19, 299 |
81 | Gentamicin | 4件: Gentamicin; Gentamicin infusions twice a week for six months; Gentamicin sulfate; Gentamicin sulfate, injectable; | D01063 D08013 |
- |
- |
3件: 36, 113, 299 |
82 | Glutathione | 10件: Glutathione; Glutathione sodium; Gsh (glutathione); Inhaled reduced glutathione; Intranasal glutathione - (in)gsh; Oral glutathione; Oral reduced l-glutathione; Reduced glutathione; Reduced glutathione 100mg; Reduced glutathione 200mg; | D00014 D00031 |
- |
- |
2件: 6, 299 |
83 | Glycine | 4件: Flolan tm and glycine diluent; Flolan™ and glycine diluent; Glycine; Glycine buffer; | D00011 |
- |
- |
4件: 35, 86, 226, 299 |
84 | Helium | 6件: Helium; Helium / oxygen mixed gas inhalation therapy; Helium-3; Hyperpolarized helium-3; Hyperpolarized helium-3 mri; Hyperpolarized helium-3 mri of the chest; | D04420 |
- |
- |
3件: 228, 299, 330 |
85 | Helium He-3 | - | - |
- |
- |
2件: 228, 299 |
86 | Heparin | 7件: Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Heparin; Heparin 25mg inhalation powder, hard capsule; Heparin sodium; Intralipid/heparin; Low molecular weight heparin calcium injection; | D07510 |
1件: SERPINC1 |
1件: Complement and coagulation cascades |
11件: 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 |
87 | Hyaluronic acid | 5件: Hyaluronic acid; Hyaluronic acid and chondroitin sulfate; Hyaluronic acid inhalation solution; Hyaluronic acid/chondroitin sulfate; Standard care hyaluronic acid eye drops; | D08043 |
- |
- |
7件: 46, 53, 70, 97, 226, 231, 299 |
88 | Hydrocortisone | 22件: Combination oral budesonide and rectal hydrocortisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortef (hydrocortisone); Dual release hydrocortisone (plenadren); Hydrocortisone; Hydrocortisone (solucortef); Hydrocortisone 10mg tablet; Hydrocortisone 20mg tablets; Hydrocortisone cream; Hydrocortisone cream 1%; Hydrocortisone cream 10mg/g fna fagron; Hydrocortisone efcortesol & solu-cortef; Hydrocortisone modified release capsules; Hydrocortisone roussel; Hydrocortisone sodium acetate; Hydrocortisone sodium phosphate; Hydrocortisone sodium succinate; Hydrocortisone takeda, tabletter; Mesalazine with hydrocortisone sodium succinate; Solu-cortef (hydrocortisone); Subcutaneous hydrocortisone; Subcutaneous hydrocortisone 10mg; | D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 6, 53, 75, 78, 81, 83, 97, 299 |
89 | Hydrocortisone acetate | - | D00165 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 6, 53, 75, 78, 81, 83, 97, 299 |
90 | Hydroxychloroquine | 16件: Hydroxychloroquine; Hydroxychloroquine (z0188); Hydroxychloroquine + prednisone; Hydroxychloroquine high; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Hydroxychloroquine sulfate; Hydroxychloroquine sulphate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sirolimus and hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Versus hydroxychloroquine; | D08050 |
- |
- |
18件: 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
91 | Ibuprofen | 5件: Ibuprofen; Ibuprofen 200mg; Ibuprofen pch tablet 600mg; Rebif new formulation + ibuprofen prn; Rebif new formulation + prophylactic ibuprofen; | D00126 D01122 D04490 D06606 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
6件: 13, 46, 65, 113, 271, 299 |
92 | Indium | 5件: Indium; Indium 111-radiolabelled anti-cd66; Indium-111 pentreotide; Indium-dtpa; Indium 111 labelled anti-cd66; | - |
- |
- |
3件: 28, 84, 299 |
93 | Insulin Detemir | 3件: Insulin detemir; Insulin detemir [rdna origin] injection; Once-daily insulin detemir; | D04539 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 299 |
94 | Insulin glargine | 1件: Insulin glargine; | D03250 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 299 |
95 | Interferon gamma-1b | 2件: Interferon gamma-1b; Interferon gamma-1b (actimmune); | D00747 |
2件: IFNGR1, IFNGR2 |
19件: Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Salmonella infection, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
7件: 65, 85, 90, 228, 299, 301, 326 |
96 | Inulin | 2件: Inulin; Oligofructose enriched inulin; | D00171 |
- |
- |
2件: 96, 299 |
97 | Isoxaflutole | - | - |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
98 | Itraconazole | 2件: Itraconazole; Itraconazole/voriconazole; | D00350 |
- |
- |
4件: 3, 65, 227, 299 |
99 | Ivacaftor | 31件: Cf patients with a g551d mutation and treated with ivacaftor; Deuterated ivacaftor; Elexacaftor-tezacaftor-ivacaftor exposure; Ivacaftor; Ivacaftor 125mg tablet; Ivacaftor 150 mg or 250 mg; Ivacaftor 25 mg/75 mg; Ivacaftor 75 mg/150 mg; Ivacaftor exposed; Ivacaftor+lumacaftor; Ivacaftor/kalydeco; Lumacaftor / ivacaftor; Lumacaftor plus ivacaftor; Lumacaftor plus ivacaftor combination; Lumacaftor-ivacaftor; Lumacaftor-ivacaftor treatment; Lumacaftor/ ivacaftor; Lumacaftor/ivacaftor; Lumacaftor/ivacaftor 100mg/125mg tablets; Lumacaftor/ivacaftor 200mg/125mg tablets; Lumacaftor/ivacaftor 200mg/83mg tablet; Tezacaftor/ivacaftor; Tezacaftor/ivacaftor + ivacaftor; Tezacaftor/ivacaftor 100mg/150mg; Vx-659/tezacaftor/ivacaftor; Vx-661/ ivacaftor; Vx-661/ivacaftor; Vx-661/ivacaftor (vx-770) 100mg/150 mg; Vx-661/ivacaftor 100 mg/ 150 mg; Vx-661/ivacaftor 100mg/150mg; Vx-661/ivacaftor 50 mg/ 75 mg; | D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
100 | KB001 | 2件: Kb001; Kb001-a; | - |
- |
- |
1件: 299 |
101 | Kappadione | - | D04908 |
- |
- |
1件: 299 |
102 | L-Alanine | 1件: L-alanine; | D00012 |
- |
- |
3件: 13, 298, 299 |
103 | L-Arginine | 3件: L-arginine; Ng-monomethyl-l-arginine; Ng-monomethyl-l-arginine (drug); | D02982 |
- |
- |
5件: 67, 78, 113, 251, 299 |
104 | L-Glutamine | 1件: L-glutamine; | D00015 |
- |
- |
6件: 87, 96, 97, 113, 245, 299 |
105 | L-Leucine | 1件: L-leucine; | D00030 |
- |
- |
7件: 5, 6, 7, 127, 283, 284, 299 |
106 | L-Lysine | 2件: L-lysine; L-lysine-n-acetylcysteinate; | D02304 |
- |
- |
4件: 13, 97, 228, 299 |
107 | Lactic acid | 3件: L-lactic acid; Lactic acid; Lactic acid producing organisms; | D00111 |
- |
- |
3件: 51, 265, 299 |
108 | Lactobacillus reuteri | 1件: Lactobacillus reuteri; | - |
- |
- |
2件: 97, 299 |
109 | Lancovutide | - | - |
- |
- |
1件: 299 |
110 | Lansoprazole | 4件: Lansoprazole; Lansoprazole, amoxicillin, clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms; | D00355 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 63, 71, 98, 166, 222, 299 |
111 | Lenomorelin | - | - |
- |
- |
3件: 6, 78, 299 |
112 | Levofloxacin | 2件: Levofloxacin; Mp-376 (levofloxacin solution for inhalation); | D00588 D08120 |
- |
- |
2件: 84, 299 |
113 | Linezolid | 1件: Linezolid; | D00947 |
- |
- |
1件: 299 |
114 | Losartan | 8件: Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan bluefish 50 mg; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Sildenafil and losartan; | D00357 D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
115 | Lubiprostone | 1件: Lubiprostone; | D04790 |
1件: CLCN2 |
1件: Mineral absorption |
4件: 6, 13, 290, 299 |
116 | Lucinactant | 2件: Lucinactant; Lucinactant first; | D04792 |
- |
- |
1件: 299 |
117 | Lumacaftor | 12件: Ivacaftor+lumacaftor; Lumacaftor; Lumacaftor / ivacaftor; Lumacaftor plus ivacaftor; Lumacaftor plus ivacaftor combination; Lumacaftor-ivacaftor; Lumacaftor-ivacaftor treatment; Lumacaftor/ ivacaftor; Lumacaftor/ivacaftor; Lumacaftor/ivacaftor 100mg/125mg tablets; Lumacaftor/ivacaftor 200mg/125mg tablets; Lumacaftor/ivacaftor 200mg/83mg tablet; | D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
118 | MS-1819 | 2件: Ms1819; Ms1819-sd; | - |
- |
- |
2件: 298, 299 |
119 | Mannitol | 7件: Dp mannitol; Idpm: inhaled dry powder mannitol; Inhaled dry powder mannitol; Inhaled mannitol; Mannitol; Mannitol + pulmozyme; Mannitol inhalation powder; | D00062 |
- |
- |
3件: 6, 96, 299 |
120 | Mecasermin | 2件: Mecasermin; Mecasermin [rdna origin] 10mg/ml solution; | D03297 D04870 |
2件: GHR, IGF1R |
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
6件: 65, 78, 96, 168, 265, 299 |
121 | Menadiol diphosphate | 1件: Menadiol diphosphate; | D08176 |
- |
- |
1件: 299 |
122 | Meropenem | 8件: Continuous infusion meropenem; Intermittent, short infusion meropenem; Iv meropenem; Meropenem; Meropenem fresenius kabi; Meropenem fresenius kabi 1 g poeder voor oplossing voor injectie of infusie; Meropenem infusion; Meropenem trihydrate; | D02222 D08185 |
- |
- |
1件: 299 |
123 | Metformin | 12件: 750 mg metformin and 7.5 g l-citrulline daily p.o.; Glucophage (metformin); L-citrulline and metformin & l-citrulline; Metformin; Metformin (generic); Metformin 500mg; Metformin and metformin & l-citrulline; Metformin hcl; Metformin hydrochloride; Metformin/cp-690,550; Pioglitazone or metformin; Sitagliptin and metformin; | D00944 D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
17件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
124 | Miglustat | 3件: Miglustat; Miglustat (zavesca); Zavesca (miglustat); | D05032 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
3件: 19, 256, 299 |
125 | Minocycline | 7件: Combination of minocycline and mtx or mtx alone; Glatiramer acetate with minocycline; Lovastatin, then minocycline/lovastatin; Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Minocycline, then minocycline/lovastatin; | D00850 D05045 |
- |
- |
14件: 2, 6, 8, 13, 46, 84, 85, 90, 94, 162, 201, 206, 280, 299 |
126 | Molgramostim | 4件: Molgramostim; Molgramostim 300 mcg nebuliser solution; Molgramostim nebuliser solution 300 mcg; Molgramostim nebulizer solution; | D05066 |
1件: CSF2RA |
4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
2件: 229, 299 |
127 | Moxifloxacin | 5件: Avelox- moxifloxacin; Moxifloxacin; Moxifloxacin 400 mg; Moxifloxacin hydrochloride; Moxifloxacin infusion; | D00874 D08237 |
- |
- |
8件: 2, 6, 46, 49, 85, 86, 240, 299 |
128 | Mupirocin | 2件: Mupirocin; Mupirocin intranasal creme; | D01076 D02195 |
- |
- |
2件: 227, 299 |
129 | N-6022 | 1件: N6022; | - |
- |
- |
1件: 299 |
130 | Neomycin | 1件: Neomycin; | D08260 |
- |
- |
4件: 96, 97, 296, 299 |
131 | Nitrate | 5件: Gallium nitrate; Nitrate; Pilocarpine nitrate 5%; Sodium nitrate; Sodium nitrate - double dose; | D02313 |
- |
- |
3件: 58, 113, 299 |
132 | Nitric Oxide | 11件: Inhaled nitric oxide; Inhaled nitric oxide & inopulse delivery; Inhaled nitric oxide - 30 mcg/kg ibw/hr; Inhaled nitric oxide 5,10,15 mcg/kg ibw/hr; Inhaled nitric oxide 75 mcg/kg ibw/hr; Nitric oxide; Nitric oxide 160 ppm; Nitric oxide for inhalation; Nitric oxide generated by the geno nitrosyl delivery system; Nitric oxide plus oxygen; Nitric oxide supplement; | D00074 |
- |
- |
7件: 46, 85, 86, 98, 251, 294, 299 |
133 | Nitrite | 9件: 120 mg sodium nitrite inhalation solution; 15 mg sodium nitrite inhalation solution; 25% mtd sodium nitrite inhalation solution; 45 mg sodium nitrite inhalation solution; 90 mg sodium nitrite inhalation solution; Air001 (sodium nitrite inhalation solution); Nitrite; Sodium nitrite; Sodium nitrite inhalation solution; | - |
- |
- |
2件: 86, 299 |
134 | Nitrogen | 1件: Nitrogen; | D00083 |
- |
- |
5件: 5, 6, 17, 211, 299 |
135 | Norethisterone | - | D00182 D00953 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
4件: 13, 46, 49, 299 |
136 | Norgestimate | 2件: Norgestimate; Ortho-cyclen, ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg; | D05209 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 299 |
137 | Omalizumab | 3件: Omalizumab; Omalizumab (xolair); Rituximab combined with omalizumab; | D05251 |
1件: FCER1A |
4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
6件: 53, 65, 98, 162, 226, 299 |
138 | Omega-3 fatty acids | 6件: Dietary supplement omega3 fatty acids aand vitamins; Lipoic acid and omega-3 fatty acids; Omega 3 fatty acids; Omega-3 fatty acids; Omega3 fatty acids; Triomar™ (omega-3 fatty acids); | - |
- |
- |
7件: 13, 46, 49, 66, 79, 96, 299 |
139 | Omeprazole | 16件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Clartihromycin, amoxicillin, and omeprazole; Diclofenac + omeprazole; Dimebon + omeprazole; Naproxen 500 mg tablets (pn 200 minus omeprazole); Omeprazole; Omeprazole (uk licensed generic product); Omeprazole 20 mg; Omeprazole 20mg; Omeprazole 20mg bid; Omeprazole 40 mg; Omeprazole 40mg capsule; Omeprazole magnesium; Omeprazole rectally 1mg/kg; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Rifaximin+omeprazole+miralax; | D00455 D01207 D05259 D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
140 | Oseltamivir | 1件: Oseltamivir; | D00900 D08306 |
- |
- |
1件: 299 |
141 | Oxygen | 9件: Continuous oxygen; Helium / oxygen mixed gas inhalation therapy; Medical air vs oxygen; Medical grade oxygen; Nitric oxide plus oxygen; Oxygen; Oxygen 40 %; Oxygen supplementation; Perfluorinated gas/oxygen mixture; | D00003 |
- |
- |
18件: 5, 6, 17, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 211, 226, 299, 330 |
142 | PTI-428 | 1件: Pti-428; | - |
- |
- |
1件: 299 |
143 | PTI-801 | 1件: Pti-801; | - |
- |
- |
1件: 299 |
144 | Pancrelipase | 9件: Pancrecarb® (pancrelipase); Pancrelipase; Pancrelipase amylase; Pancrelipase delayed release; Pancrelipase delayed release capsule; Pancrelipase microtablets; Pancrelipase with bicarbonate; Pancrelipase/pancreas powder; Viokase 16 (pancrelipase) + nexium; | D05349 |
- |
- |
4件: 96, 97, 298, 299 |
145 | Pancrelipase amylase | 1件: Pancrelipase amylase; | - |
- |
- |
4件: 96, 97, 298, 299 |
146 | Pancrelipase lipase | - | - |
- |
- |
4件: 96, 97, 298, 299 |
147 | Pancrelipase protease | - | - |
- |
- |
4件: 96, 97, 298, 299 |
148 | Pentetic acid | - | D05422 |
- |
- |
3件: 13, 28, 299 |
149 | Phenylbutyric acid | - | D05868 |
- |
- |
10件: 2, 3, 6, 8, 93, 94, 244, 251, 297, 299 |
150 | Phosphate ion | - | - |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
151 | Pilocarpine | 2件: Pilocarpine; Pilocarpine nitrate 5%; | D00525 D02200 D05478 |
2件: CHRM2, CHRM3 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
3件: 6, 53, 299 |
152 | Pioglitazone | 6件: Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl; | D00945 D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
153 | Piperacillin | 7件: Continuous infusion piperacillin tazobactam; Intermittent, short infusion piperacillin tazobactam; Iv piperacillin-tazobactam; Piperacillin; Piperacillin sodium; Piperacillin with tazobactam (tazocin); Piperacillin-tazobactam combination product; | D00466 D02251 D08380 |
- |
- |
1件: 299 |
154 | Plerixafor | 3件: Plerixafor; Plerixafor for conditioning before hsct.; Plerixafor mobilization of autologous cd117 stem cells; | D08971 |
1件: CXCR4 |
12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
4件: 51, 65, 285, 299 |
155 | Polymyxin B | - | D01066 D08401 |
- |
- |
1件: 299 |
156 | Posaconazole | 2件: Posaconazole; Posaconazole (psz); | D02555 |
- |
- |
3件: 60, 65, 299 |
157 | Pramocaine | - | D08407 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 299 |
158 | Prednisolone | 46件: Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroid (prednisolone); Corticosteroid treatment (methylprednisolone or prednisolone); Corticosteroids (prednisone or prednisolone); Etanercept, methotrexate, prednisolone; Glucocorticoid (prednisone or prednisolone); Intravenous methyl prednisolone; Long-circulating liposomal prednisolone; Low dose prednisolone; Medium dose prednisolone; Methotrexate - etanercept - prednisolone arm; Methyl prednisolone; Methylprednisolone or prednisolone; Oral prednisolone; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Peg-liposomal prednisolone sodium phosphate; Prednisolone; Prednisolone & dipyridamole; Prednisolone + mabthera; Prednisolone 1mg tablets; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone 5mg tablet; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisolone and taper; Prednisolone sodium metasulphobenzoate; Prednisolone sodium phosphate; Prednisolone sodium succinate; Prednisolone tablets b.p. 5mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednisone or prednisolone; Prednisone/prednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; | D00472 D00980 D00981 D00982 D01239 D01998 D02156 D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
159 | Prednisone | 57件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); | D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
44件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
160 | Pyruvic acid | - | - |
- |
- |
2件: 58, 299 |
161 | Quercetin | 3件: Dasatinib + quercetin; Quercetin; Quercetin (dietary supplement); | - |
- |
- |
5件: 84, 85, 192, 285, 299 |
162 | Repaglinide | 2件: Repaglinide; Repaglinide and insulin; | D00594 |
2件: ABCC8, KCNJ11 |
4件: ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus |
2件: 6, 299 |
163 | Reparixin | 1件: Reparixin; | D08984 |
2件: CXCR1, CXCR2 |
7件: Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, Human cytomegalovirus infection, Phospholipase D signaling pathway, Viral protein interaction with cytokine and cytokine receptor |
2件: 298, 299 |
164 | Rifampicin | 1件: Rifampicin; | D00211 |
- |
- |
7件: 6, 13, 17, 46, 84, 86, 299 |
165 | Riociguat | 12件: Adempas (riociguat, bay63-2521); Riociguat; Riociguat (adempas, bay63-2521); Riociguat (bay63-2521); Riociguat coated tablet 0.5 mg; Riociguat coated tablet 1.0 mg; Riociguat coated tablet 1.5 mg; Riociguat coated tablet 2.0 mg; Riociguat coated tablet 2.5 mg; Riociguat granules 0.3% for oral application; Riociguat oral product; Riociguat pill; | D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
6件: 51, 84, 86, 88, 225, 299 |
166 | Ritonavir | 9件: Atazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis); Atazanavir/ritonavir; Lopinavir / ritonavir; Lopinavir/ritonavir; Lopinavir/ritonavir + nevirapine; Lopinavir/ritonavir + zidovudine + lamivudine; Ritonavir; Ritonavir (norvir); Saquinavir and ritonavir; | D00427 |
- |
- |
5件: 2, 86, 130, 265, 299 |
167 | Roflumilast | 2件: Oral roflumilast; Roflumilast; | D05744 |
4件: PDE4A, PDE4B, PDE4C, PDE4D |
5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
2件: 84, 299 |
168 | Rosuvastatin | 6件: Calcium rosuvastatin; Crestor tablets (calcium rosuvastatin) film-coated tablets; Rosuvastatin; Rosuvastatin 10 mg; Rosuvastatin 20mg; Rosuvastatin calcium; | D01915 D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
8件: 6, 46, 49, 51, 79, 96, 271, 299 |
169 | Roxithromycin | 1件: Roxithromycin; | D01710 |
- |
- |
2件: 46, 299 |
170 | Salbutamol | 5件: Nebulized combination ipratropium bromide with salbutamol; R-salbutamol; R-salbutamol sulphate; Salbutamol; Salbutamol 4mg tablet; | D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
171 | Salmeterol | 1件: Salmeterol; | D00687 D05792 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 299 |
172 | Saxagliptin | 1件: Saxagliptin; | D08996 |
1件: DPP4 |
1件: Protein digestion and absorption |
1件: 299 |
173 | Seliciclib | 1件: Seliciclib; | - |
- |
- |
2件: 75, 299 |
174 | Sildenafil | 25件: 20 mg sildenafil citrate by mouth; 5% sildenafil cream; Access program - sildenafil citrate, viagra, revatio; Acute (1 hour) sildenafil; Bosentan and sildenafil; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Oral sildenafil; Sildenafil; Sildenafil (50 mg); Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil 20 mg tablets; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil 40mg oral capsule; Sildenafil and losartan; Sildenafil citrate; Sildenafil citrate (uk-92,480); Sildenafil singly or in association with bosentan; Sildenafil therapy; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Sub-chronic (4 weeks) sildenafil; Tadalafil and sildenafil; | D02229 D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
16件: 6, 46, 50, 51, 85, 86, 96, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
175 | Simvastatin | 11件: Encapsulated simvastatin tablets; Ezetimibe+simvastatin drug combination; Simvastatin; Simvastatin 20mg/5ml oral suspension; Simvastatin 40 mg film-coated tablets; Simvastatin 40mg; Simvastatin alternova; Simvastatin susp.; Simvastatin treatment for 28 days; Simvastatin-ratiopharm; Simvastatin-ratiopharm®; | D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
176 | Sitagliptin | 2件: Sitagliptin; Sitagliptin and metformin; | D08516 |
1件: DPP4 |
1件: Protein digestion and absorption |
3件: 75, 233, 299 |
177 | Sodium bicarbonate | 2件: Sodium bicarbonate; Sodium bicarbonate bp; | D01203 |
- |
- |
1件: 299 |
178 | Sodium chloride | 14件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; | D02056 |
- |
- |
19件: 6, 11, 13, 14, 17, 34, 46, 51, 53, 67, 78, 86, 97, 168, 193, 227, 228, 288, 299 |
179 | Somatotropin | 2件: Recombinant human somatotropin; Somatotropin; | D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
18件: 2, 3, 13, 19, 46, 74, 75, 78, 96, 113, 191, 193, 195, 236, 265, 274, 276, 299 |
180 | Sorbitol | 2件: D-sorbitol; Sorbitol; | D00096 |
- |
- |
3件: 10, 28, 299 |
181 | Succinic acid | - | - |
- |
- |
1件: 299 |
182 | Sulfamethoxazole | 6件: Sulfamethoxazole; Trimethoprim sulfamethoxazole; Trimethoprim sulfamethoxazole (tmp/smx); Trimethoprim-sulfamethoxazole; Trimethoprim/sulfamethoxazole; Trimethoprim/sulfamethoxazole (tmp/smx); | D00447 |
- |
- |
4件: 44, 49, 85, 299 |
183 | Sulfate ion | - | - |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
184 | Sunflower oil | 2件: High oleic sunflower oil; Sunflower oil; | D09006 |
- |
- |
3件: 46, 240, 299 |
185 | Tacrolimus | 13件: Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Rectal tacrolimus; Tacrolimus; Tacrolimus (prograf®); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus with methotrexate; | D00107 D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
30件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 86, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
186 | Talniflumate | 1件: Talniflumate; | D02701 |
- |
- |
1件: 299 |
187 | Tauroursodeoxycholic acid | 2件: Tauroursodeoxycholic acid; Tauroursodeoxycholic acid capsules; | - |
- |
- |
4件: 2, 13, 93, 299 |
188 | Tazobactam | 10件: Ceftolozane/tazobactam; Continuous infusion piperacillin tazobactam; Intermittent, short infusion piperacillin tazobactam; Iv piperacillin-tazobactam; Piperacillin with tazobactam (tazocin); Piperacillin-tazobactam combination product; Piperacilline/tazobactam fresenius kabi 2 g/0,25 g poeder voor oplossing voor infusie; Piperacilline/tazobactam fresenius kabi 4 g/0,5 g poeder voor oplossing voor infusie; Tazobactam; Tazobactam sodium; | D00660 |
- |
- |
1件: 299 |
189 | Technetium Tc-99m sulfur colloid | - | D06048 |
- |
- |
1件: 299 |
190 | Tedizolid | 3件: Tedizolid; Tedizolid iv/po; Tedizolid po/iv; | D09685 |
- |
- |
1件: 299 |
191 | Telavancin | 2件: Telavancin; Telavancin injection; | - |
- |
- |
1件: 299 |
192 | Tezacaftor | 7件: Elexacaftor-tezacaftor-ivacaftor exposure; Tezacaftor; Tezacaftor (tez); Tezacaftor/ivacaftor; Tezacaftor/ivacaftor + ivacaftor; Tezacaftor/ivacaftor 100mg/150mg; Vx-659/tezacaftor/ivacaftor; | D11041 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
193 | Theophylline | 1件: Theophylline; | D00371 D01712 D02017 D06103 D06104 |
19件: ADORA1, ADORA2A, ADORA2B, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B |
24件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 236, 299 |
194 | Ticarcillin | 4件: Continuous infusion ticarcillin-clavulanate; Intermittent, short infusion ticarcillin-clavulanate; Iv ticarcillin-clavulanate; Ticarcillin; | D08593 |
- |
- |
1件: 299 |
195 | Tiotropium | 7件: Tiotropium; Tiotropium bromide high; Tiotropium bromide low; Tiotropium bromide medium; Tiotropium bromide monohydrate; Tiotropium respimat; Tiotropium respimat 1.25 microgram solution for inhalation; | - |
- |
- |
3件: 55, 85, 299 |
196 | Tobramycin | 27件: Ceftazidime and tobramycin; Dry powder tobramycin; Inhaled tobramycin; Iv tobramycin; Tip (tobramycin inhalation powder); Tis (tobramycin inhalation solution); Tobi (tobramycin); Tobramycin; Tobramycin (gernebcin®); Tobramycin / bramitob; Tobramycin / tobi; Tobramycin 100 pari; Tobramycin dry powder; Tobramycin for inhalation; Tobramycin inhalation powder; Tobramycin inhalation powder (tip); Tobramycin inhalation solution; Tobramycin inhalation solution (tis); Tobramycin inhalation solution using a pari lc® plus nebulizer.; Tobramycin nebulized nasally; Tobramycin powder; Tobramycin solution for inhalation; Tobramycin solution for inhalation (tobi); Tobramycin solution for inhalation 300 mg; Tobramycin steri-neb 300 mg/5 ml, inhalation solution; Tobramycin sulfate; Vantobra (tobramycin); | D00063 D02542 |
- |
- |
1件: 299 |
197 | Tocofersolan | - | D06174 |
- |
- |
1件: 299 |
198 | Tocotrienol | 3件: Alpha-tocotrienol quinone; Egcg + tocotrienol; Tocotrienol; | - |
- |
- |
2件: 156, 299 |
199 | Topramezone | - | - |
- |
- |
7件: 6, 13, 46, 50, 96, 97, 299 |
200 | Trimethoprim | 7件: Trimethoprim; Trimethoprim sulfamethoxazole; Trimethoprim sulfamethoxazole (tmp/smx); Trimethoprim sulfate; Trimethoprim-sulfamethoxazole; Trimethoprim/sulfamethoxazole; Trimethoprim/sulfamethoxazole (tmp/smx); | D00145 D06236 |
- |
- |
6件: 36, 44, 49, 60, 85, 299 |
201 | Tromethamine | 2件: Ketorolac tromethamine; Tromethamine; | D00396 |
- |
- |
3件: 51, 226, 299 |
202 | Turmeric | 2件: Standardized turmeric root extract; Turmeric; | - |
- |
- |
4件: 140, 144, 158, 299 |
203 | Uridine | 1件: Uridine; | - |
- |
- |
1件: 299 |
204 | Ursadiol | - | - |
- |
- |
6件: 8, 20, 93, 97, 234, 299 |
205 | Ursodeoxycholic acid | 9件: Udca (ursodeoxycholic acid); Ursodeoxycholic acid; Ursodeoxycholic acid (udca); Ursodeoxycholic acid (urso); Ursodeoxycholic acid 300mg capsule; Ursodeoxycholic acid 300mg tablet; Ursodeoxycholic acid capsules; Ursodeoxycholic acid combination of immunosuppressive agents; Ursodiol (ursodeoxycholic acid, udca); | D00734 |
1件: NR1H4 |
1件: Bile secretion |
12件: 6, 8, 20, 67, 84, 93, 94, 95, 96, 97, 234, 299 |
206 | VX-659 | 3件: Vx-659; Vx-659/tez/iva; Vx-659/tezacaftor/ivacaftor; | - |
- |
- |
1件: 299 |
207 | Valganciclovir | 3件: Valganciclovir; Valganciclovir (vgc); Valganciclovir [valcyte]; | D02495 |
- |
- |
6件: 28, 60, 85, 97, 299, 331 |
208 | Vancomycin | 9件: Inhaled vancomycin; Iv vancomycin hydrochloride; Oral vancomycin; Vancomycin; Vancomycin inhalation powder; Vancomycin pre-treat; Vancomycin pre-treatment; With u-vanco (vancomycin hydrochloride); Without u-vanco (vancomycin hydrochloride); | D00212 D00926 |
- |
- |
7件: 46, 70, 94, 96, 97, 296, 299 |
209 | Vardenafil | 2件: Vardenafil; Vardenafil (hidrocloride); | D02731 D03260 D08668 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
3件: 13, 86, 299 |
210 | Vitamin D | 16件: 10000iu vitamin d; 19 nor vitamin d; 25oh-vitamin d; 5000iu vitamin d; Alendronate versus alfacalcidol (1-alpha oh vitamin d); High-dose vitamin d (2000 iu per day); Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Standard-dose vitamin d (400iu per day); Verum arm receiving vitamin d oil; Vitamin d; Vitamin d 100ug; Vitamin d 10ug; Vitamin d 25(oh)d; Vitamin d in arm b; Vitamin d oil; Vitamin d powder; | - |
- |
- |
18件: 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
211 | Vitamin E | 8件: Coenzyme q10 with vitamin e; Omega-3 and vitamin e supplementation; Vitamin c 10mg/kg vitamin e 10 mg/kg; Vitamin e; Vitamin e - tgps; Vitamin e 800iu; Vitamin e supplement; Vitamin e/selenium; | D02331 |
- |
- |
12件: 2, 6, 13, 20, 46, 49, 90, 96, 97, 206, 299, 317 |
212 | Voriconazole | 2件: Itraconazole/voriconazole; Voriconazole; | D00578 |
- |
- |
2件: 60, 299 |
213 | Water | 13件: 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep; | D00001 |
- |
- |
22件: 2, 5, 6, 13, 17, 19, 28, 35, 46, 53, 57, 63, 65, 67, 78, 84, 97, 193, 226, 271, 278, 299 |
214 | Xenon | 7件: Hyperpolarized 129 xenon gas comparing idiopathic pulmonary fibrosis (ipf) treatment; Hyperpolarized 129-xenon gas; Hyperpolarized xenon; Hyperpolarized xenon gas; Xenon; Xenon contrast agent; Xenon-129; | D01901 D06339 |
- |
- |
5件: 22, 85, 228, 231, 299 |
215 | Xenon-133 | - | - |
- |
- |
5件: 22, 85, 228, 231, 299 |
216 | Xylitol | 1件: Xylitol; | D00061 |
- |
- |
2件: 53, 299 |
217 | Zinc | 8件: Adeno-associated virus serotype 2/6 encoding left side-zinc finger nuclease (zfn1), sb-a6p-zleft vector; Adeno-associated virus serotype 2/6 encoding right side-zinc finger nuclease (zfn2), sb-a6p-zright vector; Zinc; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zinc and copper; Zinc gluconate; | - |
- |
- |
4件: 2, 19, 171, 299 |
218 | Zinc acetate | 3件: Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; | D06408 |
- |
- |
7件: 49, 51, 70, 86, 171, 256, 299 |
219 | Zinc chloride | - | D02058 |
- |
- |
4件: 2, 19, 171, 299 |
220 | Zoledronic acid | 4件: Lonafarnib, zoledronic acid, and pravastatin; Zoledronic acid; Zoledronic acid 5mg/bag 100ml inj; Zoledronic acid monohydrate; | D01968 D06378 D06379 D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
11件: 6, 13, 46, 65, 93, 95, 96, 271, 274, 299, 333 |